Back to Search
Start Over
The Current Status and Perspectives of Delivery Strategy for Boronbased Drugs
- Source :
- Current Medicinal Chemistry. 26:5019-5035
- Publication Year :
- 2019
- Publisher :
- Bentham Science Publishers Ltd., 2019.
-
Abstract
- Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.
- Subjects :
- inorganic chemicals
medicine.medical_specialty
chemistry.chemical_element
Biochemistry
Bone health
Trade name
03 medical and health sciences
0302 clinical medicine
Drug Discovery
medicine
Intensive care medicine
Boron
Clinical treatment
030304 developmental biology
Pharmacology
0303 health sciences
Tavaborole
Bortezomib
business.industry
Organic Chemistry
chemistry
030220 oncology & carcinogenesis
Anti cancer drugs
Molecular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 09298673
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Current Medicinal Chemistry
- Accession number :
- edsair.doi.dedup.....fe938f8799a7473124142532488770bc